2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4597 Contemporary real-world clinical characteristics and treatment patterns of 1555 patients with myelofibrosis in the United States

Jingbo Yu, MD, PhD, Xinshuo Ma, MS2, Pam Kumparatana, MSSW, MPH3, Catherine Park, MHI4, Nigel Rozario, PhD5, Valkal Bhatt, PharmD6
1 Incyte Corporation, Wilmington, Delaware, United States
2 Komodo Health, New York, New York, United States
3 Komodo Health, New York, New York, United States
4 Komodo Health, New York, New York, United States
5 Komodo Health, New York, New York, United States
6 Incyte Corporation, Wilmington, Delaware, United States

Background: Myelofibrosis (MF) is a progressive myeloproliferative neoplasm characterized by bone marrow fibrosis leading to anemia, splenomegaly, debilitating symptoms, and reduced survival. The treatment landscape continues to evolve, with several FDA-approved Janus kinase (JAK) inhibitors, including ruxolitinib (RUX), fedratinib (FED), pacritinib (PAC), momelotinib (MOM), and RUX XR. The objective of this study is to describe contemporary clinical characteristics and treatment patterns of patients with MF in the United States.

Methods: This retrospective study analyzed de-identified administrative closed-claims data from Komodo Research Dataset and Komodo Laboratory Results dated 1Sep2023–30May2026. This study included adult patients with MF diagnosis and treatment; index was the date of first MF treatment after MF diagnosis. Included patients also must have had continuous enrollment in medical and pharmacy plans for ≥3 months before and ≥6 months after index, and no evidence of bone marrow transplant.

Results: Among a total of 1555 patients included, first-line (1L) MF treatments received were RUX (n=740 [47.6%]), hydroxyurea (HU; n=468 [30.1%]), MOM (n=128 [8.2%]), anagrelide (ANA, n=63 [4.1%]), PAC (n=40 [2.6%]), FED (n=10 [0.6%]), and other. Among all patients, median (IQR) age was 74.0 (66.0–80.0) years, 73.6% were White, and patients predominantly had Medicare (74.1%) or commercial insurance (19.9%); these characteristics were generally comparable between treatment groups. Overall (and by top 3 1L treatments), 51.8% of patients were female (RUX│HU│MOM, 49.5%│57.7%│38.3%). The proportion of patients overall with post–polycythemia vera (PV)/post–essential thrombocythemia (ET) MF was 47.8% (RUX│HU│MOM, 46.4%│49.4%│37.5%).

Based on diagnosis codes, 48.2% of patients overall had a diagnosis of anemia at baseline (RUX│HU│MOM, 51.6%│37.0%│73.4%), and 16.2% had cytopenia (RUX│HU│MOM, 14.9%│8.3%│30.5%). Among the 239 patients overall who had laboratory data available at baseline (RUX│HU│MOM, n=117│n=66│n=19), median (IQR) hemoglobin (Hb) levels at index were 11.0 (9.5–12.8) g/dL (RUX│HU│MOM, 10.5 [9.0–12.2]│12.2 [10.4–13.4]│7.4 [6.3–9.4]). Median (IQR) platelet counts at index were 315 (203−528) × 103/µL (RUX│HU│MOM, 257 [175–383]│451 [312–663]│242 [75–287]). During the 3-month baseline, 28.9% of patients were on anemia-supportive care: 13.4% received erythropoiesis-stimulating agents (ESAs; RUX│HU│MOM, 15.5%│6.2%│25.8%), 12.9% blood transfusions (13.2%│3.6%│39.8%), 8.8% corticosteroids (7.6%│8.8%│8.6%), 1.3% luspatercept (1.2%│<0.7%│6.3%), and 1.0% danazol (1.2%│<0.7%│3.1%).

Median (IQR) time from diagnosis to 1L treatment initiation was 24.0 (12.0–62.0) days (RUX│HU│MOM, 19.0 [9.0–32.0]│35.0 [16.0–75.0]│116.0 [29.0–224.5]). During the first 6 months of 1L treatment, 32.5% of patients received anemia-supportive care (RUX│HU│MOM, 34.4%│26.9%│49.0%). Overall, 553 (35.6%) patients received a second-line (2L) treatment during a median follow-up of 522 days. The most common 2L MF treatments were MOM (31.1%), HU (19.2%), RUX (15.4%), HU+RUX (9.4%), PAC (8.0%), and ANA (2.9%).

Conclusions: In this contemporary real-world analysis of US patients with MF, RUX was the most commonly used 1L therapy, while HU, despite lacking FDA approval for MF, was used in nearly one-third of patients. RUX was commonly used in patients with Hb ≤10.5 g/dL, while MOM was primarily considered in patients with severe anemia (Hb <8 g/dL) and patients often required anemia-supportive care during MOM treatment. Taken together, these findings suggest more than one-third of patients with MF may benefit from earlier use of an effective treatment before disease progression to an anemic state.

Jingbo Yu, MD, PhD: Incyte Corporation - Stock (publicly traded); Incyte Corporation - Current Employment